SYROSINGOPINE

US Previously Marketed

First approved in 1958

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C35H42N2O11
Molecular Weight	666.7148
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)OC1=C(OC)C=C(C=C1OC)C(=O)O[C@@H]2C[C@@H]3CN4CCC5=C(NC6=C5C=CC(OC)=C6)[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC

InChI

InChIKey=ZCDNRPPFBQDQHR-SSYATKPKSA-N

InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C35H42N2O11
Molecular Weight	666.7148
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13640910
Curator's Comment: description was created based on several sources, including http://www.inventionforce.com/inventionforce/pn/display_pn_e.php?&id=&pn=8993587

Syrosingopine, a drug derived from reserpine, which was investigated for the treatment of essential hypertension. The combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression was patented. This invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: http://www.google.com/patents/US8993587	Primary		Basic research	Unknown Approved Use Unknown
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13640910	Primary		Approved 8583	Singoserp Approved Use Unknown

Doses

Dose	Population	Adverse events
1 mg 4 times / day multiple, oral Highest studied dose Dose: 1 mg, 4 times / day Route: oral Route: multiple Dose: 1 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13640910	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/13640910	Sources: https://pubmed.ncbi.nlm.nih.gov/13640910

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MCT4 12

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
MCT4 31	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S2211124718318060 Page: 3.0	yes [IC50 2.5 uM]

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-010917	http://www.3bsc.com/index/pro_info.php?id=33415
abcr GmbH	AB168081	http://www.abcr.com/shop/en/AB168081
AHH Chemical co.,ltd	MT-58888	http://www.ahhchemical.com/product/MT-58888.html
Alfa Chemistry	AP84366	https://reagents.alfa-chemistry.com/product/syrosingopine-cas-84-36-6-17164.html
Ambinter	Amb16192922	http://www.ambinter.com/reference/16192922
Aurora Fine Chemicals LLC	K14.819.681	http://online.aurorafinechemicals.com/info?ID=K14.819.681
Chem Scene	CS-0032125	http://www.chemscene.com/84-36-6.html
ChemFaces	CFN98542	http://www.chemfaces.com/natural/Syrosingopine-CFN98542.html
ChemMol	99164369	http://www.chemmol.com/chemmol/99164369.html
Chemspace	CSSB00000053713	https://chem-space.com/CSSB00000053713
DC Chemicals	DC36785	http://www.dcchemicals.com//product_show-Syrosingopine.html
eNovation Chemicals	D672359	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672359
iChemical	EBD3077378	http://www.ichemical.com/products/84-36-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
LGC Standards	LGCFOR1970.00	https://www.lgcstandards.com/US/en/p/LGCFOR1970.00
MedChem Express	HY-N4115	https://www.medchemexpress.com/syrosingopine.html
R&D Chemicals	1691	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8266
Smolecule	S544331	http://www.smolecule.com/products/s544331
THE BioTek	bt-282900	https://www.thebiotek.com/product/inhibitors/bt-282900
Vesino Industrial Co Ltd	VA11808	http://www.vsnchem.com/goto/product/22138/

PubMed

Title	Date	PubMed
[Central and other pharmacological actions of syrosingopine (O-carbethoxysyringoyl methylreserpate)].	1973-07	4151938

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:51:44 GMT 2025` Edited by `admin` on `Mon Mar 31 17:51:44 GMT 2025`
Record UNII	PPG46JF0EG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SIRINGINA

Preferred Name

English

SYROSINGOPINE

Official Name

English

METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 4-HYDROXY

Common Name

English

SYROSINGOPINE [MART.]

Common Name

English

LONDOMIN

Brand Name

English

Syrosingopine [WHO-DD]

Common Name

English

ISOTENSE

Brand Name

English

SYROSINGOPINE [JAN]

Common Name

English

YOHIMBAN-16-CARBOXYLIC ACID, 18-((4-((ETHOXYCARBONYL)OXY)-3,5-DIMETHOXYBENZOYL)OXY)-11,17-DIMETHOXY-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-

Common Name

English

SYROSINGOPINE [MI]

Common Name

English

METHYL CARBETHOXYSYRINGOYL RESERPATE

Common Name

English

CARBETHOXYSYRINGOYL METHYLRESERPATE

Common Name

English

syrosingopine [INN]

Common Name

English

NSC-77030

Code

English

SU 3118

Code

English

NEORESERPAN

Common Name

English

SU-3118

Code

English

Classification Tree Code System Code

WHO-VATC

QC02LA09